Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03.
已完结
10
由 达姆 发布于 2025/11/25 13:27:11
DOI:10.1016/j.annonc.2025.11.007
作者：C Saura,?J Cortés,?S Modi,?S-B Kim,?E Hamilton,?S A Hurvitz,?I E Krop,?G Curigliano,?H Iwata,?S-A Im,?P Herbolsheimer,?M Karnoub,?A Boran,?Y Kuwahara,?A Egorov,?F André
文献类型：期刊论文
补充材料：只需要正文
作者：C Saura,?J Cortés,?S Modi,?S-B Kim,?E Hamilton,?S A Hurvitz,?I E Krop,?G Curigliano,?H Iwata,?S-A Im,?P Herbolsheimer,?M Karnoub,?A Boran,?Y Kuwahara,?A Egorov,?F André
文献类型：期刊论文
补充材料：只需要正文
Elsevier
其它数据库
Oxford University Press
京公网安备 11010802042870号
